Toxicological safety evaluation of gadobenate dimeglumine 0.5 M solution for injection (MultiHance®), a new magnetic resonance imaging contrast medium

Journal of Computer Assisted Tomography

Volumn 23, Issue SUPPL., 1999, Pages

  Morisetti, Alberto ^a   Bussi, Simona ^a   Tirone, Piero ^a   De Haën, Christoph ^a  

^a Bracco SpA   (Italy)

Author keywords

Gadobenate; Mutagenicity; Reproduction; Toxicity

Indexed keywords

CONTRAST MEDIA; MAGNETISM; MAMMALS; RESONANCE; TOXICITY;

CLINICAL USE; CONTRAST MEDIUM; GADOBENATE; IMAGING CONTRAST; INTRAVASCULAR; MUTAGENICITY; REPRODUCTION; SAFETY EVALUATIONS; SAFETY STUDIES; SINGLE-DOSE;

MAGNETIC RESONANCE IMAGING;

GADOBENATE DIMEGLUMINE; GADODIAMIDE; GADOLINIUM PENTETATE; GADOTERIC ACID; GADOTERIDOL;

ANIMAL CELL; ANIMAL TISSUE; CONFERENCE PAPER; CONTRAST ENHANCEMENT; DOSE RESPONSE; DRUG SAFETY; DRUG TOLERANCE; EMBRYO DEVELOPMENT; MALE; MUTAGENICITY; NONHUMAN; PRIORITY JOURNAL; RAT; REPRODUCTIVE TOXICITY; SPECIES DIFFERENCE; TOXICOKINETICS;

EID: 0033395628     PISSN: 03638715     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004728-199911001-00025     Document Type: Conference Paper

References (33)

1. Davies A, de Haën C. Gd-BOPTA/Dimeg. Drugs Fut 1991;16: 1001-3.
2. Uggeri F, Aime S, Anelli PL, et al. Novel contrast agents for magnetic resonance imaging. Synthesis and characterization of the ligand BOPTA and its Ln(III) complexes (Ln = Gd, La, Lu). X-ray structure of disodium (TPS-9-145337286-C-S)-[4-carboxy-5,8,11-tris(carboxymethyl)-1-phenyl-2-oxa-5,8, 11-triazatridecan-13-oato(5-)]gadolinate (2-) in a mixture with its enantiomer. Inorg Chem 1995;34:633-42.
3. de Haën C, Cabrini, M, Aknana L, Ratti D, Calabi L, Gozzini L. Gadobenate dimeglumine 0.5 M solution for injection (MultiHance®): Pharmaceutical formulation and physico-chemical properties of a new magnetic resonance imaging contrast medium. J Comput Assist Tomogr 1999;23 (suppl 1):S161-8.
4. de Haën C, La Ferla R, Maggioni F. Gadobenate Dimeglumine 0.5 M solution for injection (MultiHance®) as contrast agent for magnetic resonance imaging of the liver: Mechanistic studies in animals. J Comput Assist Tomogr 1999;23 (suppl 1):S169-79.
5. de Haën C, Lorusso V, Luzzani F, Tirone P. Hepatic transport of the magnetic resonance imaging contrast agent gadobenate dimeglumine in the rat. Acad Radiol 1995;2:232-8.
6. - rats of the MRI contrast agent gadobenate dimeglumine. Acad Radiol 1996;3:S452-4.
7. Finney DJ. Statistical method in biological assay. London: Griffin, 1978.
8. SAS/STAT User's guide. Release 6.03. Edition Cary, NC, SAS Institute Inc., 1988.
9. Mitruka BM. Clinical biochemical and haematological reference values in normal animal and normal humans. New York, USA: Masson Publishing, 1981.
10. Tavole Scientifiche Geigy, Ciba-Geigy Edizioni, 1985:66.
11. Rosati G, Pirovano G, Spinazzi A. Interim results of Phase II clinical testing of gadobenate dimeglumine. Invest Radiol 1994;29: S183-5.
12. Arbughi T, Bertani F, Celeste R, Grotti A, Sillari S, Tirone P. High-performance liquid chromatographic determination of the magnetic resonance imaging contrast agent gadobenate ion in plasma, urine, faeces, bile and tissues. J Chrom B Biomed Appl. 1998;713: 415-26.
13. Weimann H-J, Press W-R, Gries H. Tolerance of Extracellular Contrast Agents for Magnetic Resonance Imaging. Invest Radiol 1990;25:S49-50.
14. Cacheris WP, Quay SC, Rocklage SM. The relationship between thermodynamics and the toxicity of gadolinium complexes. Magn Reson Imaging 1990;8:467-81.
15. Weinmann H-J, Brasch RC, Press W-R, Wesbey GE. Characteristics of gadolinium-DTPA complex: a potential NMR contrast agent. AJR Am J Roentgenol 1984;142:619-24.
16. Tweedle MF, Wedeking P, Kumar K. Biodistribution of radiolabeled, formulated gadopentetate, gadoteridol, gadoterate, and gadodiamide in mice and rats. Invest Radiol 1995;30:372-80.
17. Kasokat T, Urich K. Quantification of dechelation of gadopentetate dimeglumine in rats. Arzneim-Forsch/Drug Res 1992;42:869-76.
18. Wedeking P, Kumar K, Tweedle MF. Dissociation of gadolinium chelates in mice: relationship to chemical characteristics. Magn Reson Imaging 1992;10:641-8.
19. Tweedle MF. Physicochemical properties of gadoteridol and other magnetic resonance contrast agents. Invest Radiol 1992;27:S2-6.
20. Lorusso V, Arbughi T, Tirone P, de Haën C. Pharmacokinetics and tissue distribution in animals of gadobenate ion, the magnetic resonance imaging contrast enhancing component of gadobenate dimeglumine 0.5 M solution for injection (MultiHance®). J Comput Assist Tomogr 1999;23 (suppl 1):S181-94.
21. Rosati G, Morisetti A, Tirone P. Toxicity in animals and safety in humans: the predictive value of animal studies. Toxicol Letters 1992;64/65:705-15.
22. Okazaki O, Kurata T, Yoshioka N, Hakasui H. Pharmacokinetics and stability of caldiamide sodium in rats. Arzneim-Forsch /Drug Res 1996;46:79-83.
23. Jakson G E, Wynchank S, Woudenberg M. Gadolinium (III) complex equilibria: the implications for Gd(III) MRI contrast agents. Magn Res Med 1990;16:57-66.
24. Spinazzi A, Lorusso V, Pirovano G, Kirchin MA. Safety, tolerance, biodistribution and MR imaging enhancement of the liver with gadobenate dimeglumine: results of clinical pharmacologic and pilot imaging studies in non-patient and patient volunteers. Acad Radiol 1999;6:282-91.
25. Kirchin MA, Pirovano G, Spinazzi A. Gadobenate dimeglumine (Gd-BOPTA): an overview. Invest Radiol 1998;33:798-809.
26. Hayes A. Principle and Methods of Toxicology. New York: Raven Press, 1994.
27. Günzel P, Müller N. Toxicology of contrast media for magnetic resonance imaging: a brief review. Advances in MRI Contrast 1992;1: 29-36.
28. Soltys RA. Summary of preclinical safety evaluation of gadoteridol injection. Invest Radiol 1992;27:S7-11.
29. Schöbel C, Günzel P, Müller N. Preclinical studies with dimeglumine gadopentetate (Magnevist®) for human risk assessment. Advances in MRI Contrast 1992:1:2-14.
30. Müller N, Günzel P, Schöbel C. Ionic and nonionic gadolinium-containing magnetic resonance contrast media. Comparison of effects and their reversibility in repeated dose toxicity studies in rats. Adv in MRI Contrast 1992:1:15-28.
31. Harpur ES, Worah D, Hals P-A, Holtz E, Furuhama K, Nomura H. Preclinical safety assessment and pharmacokinetics of gadodiamide injection, a new magnetic resonance imaging contrast agent. Invest Radiol 1993;28:S28-43.
32. Allard M, Doucet D, Kien P, Bonnemain B, Caillé JM. Experimental study of DOTA-gadolinium pharmacokinetics and pharmacologic properties. Invest Radiol 1988;23:S271-4.
33. Tirone P, Castano M, Cipolla P, et al. General pharmacology in experimental animals of gadobenate dimeglumine (MultiHance®), a new magnetic resonance imaging contrast agent. J Comput Assist Tomogr 1999;23 (suppl 1):S195-206.